Search hospitals > Ohio > Cincinnati
University of Cincinnati Cancer Center-UC Medical Center
Claim this profileCincinnati, Ohio 45219
Global Leader in Cancer
Global Leader in Recurrence
Conducts research for Adenocarcinoma
Conducts research for Squamous Cell Carcinoma
Conducts research for Tumors
199 reported clinical trials
27 medical researchers
Summary
University of Cincinnati Cancer Center-UC Medical Center is a medical facility located in Cincinnati, Ohio. This center is recognized for care of Cancer, Recurrence, Adenocarcinoma, Squamous Cell Carcinoma, Tumors and other specialties. University of Cincinnati Cancer Center-UC Medical Center is involved with conducting 199 clinical trials across 288 conditions. There are 27 research doctors associated with this hospital, such as Davendra P. Sohal, Trisha Wise-Draper, MD,PhD, Emily Curran, MD, and Shuchi Gulati, MD FACP.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Recurrence
Global LeaderStage IV
Stage III
Stage I
Top PIs
Davendra P. SohalUniversity of Cincinnati Medical Center4 years of reported clinical research
Studies Cancer
Studies Colorectal Cancer
23 reported clinical trials
44 drugs studied
Trisha Wise-Draper, MD,PhDUniversity of Cincinnati Medical Center4 years of reported clinical research
Studies Cancer
Studies Squamous Cell Carcinoma
19 reported clinical trials
51 drugs studied
Emily Curran, MDUniversity of Cincinnati Cancer Center-UC Medical Center4 years of reported clinical research
Expert in Leukemia
Studies Myeloid Leukemia
15 reported clinical trials
51 drugs studied
Shuchi Gulati, MD FACPUniversity of Cincinnati Medical Center4 years of reported clinical research
Studies Cancer
Studies Tumors
13 reported clinical trials
26 drugs studied
Clinical Trials running at University of Cincinnati Cancer Center-UC Medical Center
Cancer
Gastroesophageal Junction Adenocarcinoma
Esophageal Adenocarcinoma
Esophageal Carcinoma
Prostate Cancer
Squamous Cell Carcinoma
Lung Cancer
Bladder Carcinoma
Breast Cancer
Melanoma
Reduced-Intensity Chemoradiation
for Anal Cancer
This phase II trial studies how well lower-dose chemotherapy plus radiation (chemoradiation) therapy works in comparison to standard-dose chemoradiation in treating patients with early-stage anal cancer. Drugs used in chemotherapy, such as mitomycin, fluorouracil, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Giving chemotherapy with radiation therapy may kill more tumor cells. This study may help doctors find out if lower-dose chemoradiation is as effective and has fewer side effects than standard-dose chemoradiation, which is the usual approach for treatment of this cancer type.
Recruiting3 awards Phase 25 criteria
MRI Monitoring vs. Preventive Brain Radiation
for Small Cell Lung Cancer
This phase III trial studies magnetic resonance imaging (MRI) surveillance and prophylactic cranial irradiation (PCI) to see how well they work compared to MRI surveillance alone in treating patients with small cell lung cancer. MRI scans are used to monitor the possible spread of the cancer with an MRI machine over time. PCI is radiation therapy that is delivered to the brain in hopes of preventing spread of cancer into the brain. The use of brain MRI alone may reduce side effects of receiving PCI and prolong patients' lifespan. Monitoring with MRI scans alone (delaying radiation until the actual spread of the cancer) may be at least as good as the combination of PCI with MRI scans.
Recruiting2 awards Phase 322 criteria
Osimertinib + Bevacizumab
for Lung Cancer
This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Monoclonal antibodies, such as bevacizumab, may interfere with the ability of tumor cells to grow and spread. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.
Recruiting2 awards Phase 331 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at University of Cincinnati Cancer Center-UC Medical Center?
University of Cincinnati Cancer Center-UC Medical Center is a medical facility located in Cincinnati, Ohio. This center is recognized for care of Cancer, Recurrence, Adenocarcinoma, Squamous Cell Carcinoma, Tumors and other specialties. University of Cincinnati Cancer Center-UC Medical Center is involved with conducting 199 clinical trials across 288 conditions. There are 27 research doctors associated with this hospital, such as Davendra P. Sohal, Trisha Wise-Draper, MD,PhD, Emily Curran, MD, and Shuchi Gulati, MD FACP.